Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piro Lito

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|January 15, 2025
KRAS Oncoprotein Signaling in CancerPiro Lito
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2016
Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is RequiredYaohua Xue, Piro Lito
Cancer Cell|March 12, 2024
Insights into how adeno-squamous transition drives KRAS inhibitor resistanceFeng Hu, Piro Lito
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2020
Quest for Clinically Effective RAF Dimer InhibitorsJenny Y Xue, Piro Lito
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2022
Expanding the Arsenal of Clinically Active <i>KRAS</i> G12C InhibitorsKathryn C Arbour, Piro Lito
Nature Medicine|July 11, 2018
A treatment strategy for KRAS-driven tumorsTrang T Mai, Piro Lito
Nature Reviews. Clinical Oncology|August 23, 2022
The KRYSTAL-1 study of adagrasib - a new trial for KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerYonina R Murciano-Goroff, Piro Lito
Cancer Discovery|May 18, 2021
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant TumorsYulei Zhao, Jenny Y Xue, Piro Lito
Nature Medicine|November 9, 2013
Tumor adaptation and resistance to RAF inhibitorsPiro Lito, Neal Rosen, David B Solit
Cell|October 16, 2020
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in PatientsDongsung Kim, Jenny Yaohua Xue, Piro Lito
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|January 15, 2025
KRAS Oncoprotein Signaling in CancerPiro Lito
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2016
Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is RequiredYaohua Xue, Piro Lito
Cancer Cell|March 12, 2024
Insights into how adeno-squamous transition drives KRAS inhibitor resistanceFeng Hu, Piro Lito
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2020
Quest for Clinically Effective RAF Dimer InhibitorsJenny Y Xue, Piro Lito
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2022
Expanding the Arsenal of Clinically Active <i>KRAS</i> G12C InhibitorsKathryn C Arbour, Piro Lito
Nature Medicine|July 11, 2018
A treatment strategy for KRAS-driven tumorsTrang T Mai, Piro Lito
Nature Reviews. Clinical Oncology|August 23, 2022
The KRYSTAL-1 study of adagrasib - a new trial for KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerYonina R Murciano-Goroff, Piro Lito
Cancer Discovery|May 18, 2021
Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant TumorsYulei Zhao, Jenny Y Xue, Piro Lito
Nature Medicine|November 9, 2013
Tumor adaptation and resistance to RAF inhibitorsPiro Lito, Neal Rosen, David B Solit
Cell|October 16, 2020
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in PatientsDongsung Kim, Jenny Yaohua Xue, Piro Lito
Pageof 5